Session » SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

Date: Monday, November 8, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1273

A 12-week Aerobic Exercise Training Program in Women with Systemic Lupus Erythematosus (SLE) Improves Fatigue, Mitochondrial Dysfunction and Associated Interferon Gene Signature

8:30AM-10:30AM: Abstract Number: 1287

Association of Limited Health Literacy with Patient-Provider Communication in Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 1259

Association of SLE Responder Index (SRI) Attainment and Long-term Clinical Outcomes

8:30AM-10:30AM: Abstract Number: 1303

Associations Between Early Changes in Circulating B Cell Subsets and Severe Flare in Systemic Lupus Erythematosus – Results from Three Phase III Trials of Belimumab

8:30AM-10:30AM: Abstract Number: 1295

Belimumab Reduces Severe Flares in Systemic Lupus Erythematosus Across Multiple Patient Subgroups: Results of a Large Integrated Analysis

8:30AM-10:30AM: Abstract Number: 1272

Characterizing Patient and Physician Perceptions of Systemic Lupus Erythematosus (SLE) Disease Burden Using Traditional Rheumatoid Arthritis Outcomes Measures

8:30AM-10:30AM: Abstract Number: 1282

Classification of Disease Activity and Damage in Cutaneous Lupus

8:30AM-10:30AM: Abstract Number: 1298

Clinical Characteristics of Patients with Pre-pubertal Onset SLE and Disease Outcome Throughout Puberty: A Multicenter North American Longitudinal Study

8:30AM-10:30AM: Abstract Number: 1278

Clinical Outcomes in a Cohort of Puerto Ricans with Systemic Lupus Erythematosus After SARS CoV-2 Infection

8:30AM-10:30AM: Abstract Number: 1275

Digital Solution for Collection of Patient-reported Outcome Measures in Patients with Systemic Lupus Erythematosus: A Randomised, Crossover, Agreement Study

8:30AM-10:30AM: Abstract Number: 1270

Disease Severity and Healthcare Costs Associated with Chronic Kidney Disease in Patients with Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 1301

Early Increase in Circulating Memory B Cells Portends Clinical Response to Treatment in Pooled Data from Three Phase III Trials of Belimumab

8:30AM-10:30AM: Abstract Number: 1300

Effect of Time in Clinical Remission on Damage Accrual in Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 1297

Factors Associated with Employment and Work Disability in Patients with SLE: A Nested Case-control Study

8:30AM-10:30AM: Abstract Number: 1260

Factors That Impact Medication Adherence in Hospitalized Patients with Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 1288

First Year Infection Risk in SLE Patients Treated with Rituximab versus Standard of Care Treatment: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)

8:30AM-10:30AM: Abstract Number: 1262

Fish Oil Supplementation and Pro-inflammatory and Pro-Resolving Lipid Mediators in Patients with and Without Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 1267

Frailty and Emergency Department Utilization in Systemic Lupus Erythematosus: An Administrative Claims Data Analysis

8:30AM-10:30AM: Abstract Number: 1280

Generation of Evidence Supporting the Content Validity of SF-36, Lupus-Qol, and FACIT-Fatigue, and Newly Developed Patient-reported Outcome (PRO) Symptom Items to Address Conceptual Gaps for Use in Patient with Lupus Nephritis

8:30AM-10:30AM: Abstract Number: 1271

Healthcare Resource Utilization and Costs Associated with Systemic Lupus Erythematosus After Diagnosis of End-Stage Kidney Disease: Evidence from Two United States Databases

8:30AM-10:30AM: Abstract Number: 1279

Impact of Active Lupus Nephritis in Patient-Reported Outcomes from a Latin American, Multicenter Lupus Cohort

8:30AM-10:30AM: Abstract Number: 1257

Improvements in Abnormal Laboratory Tests Are Associated with Clinical Outcomes in Patients with Active Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 1281

Longitudinal Association of Baseline Frailty with Patient-Reported Outcome Measures

8:30AM-10:30AM: Abstract Number: 1299

Longitudinal Patterns of Response to Standard of Care Therapy for Lupus Nephritis: Data from the Accelerating Medicines Partnership Lupus Network

8:30AM-10:30AM: Abstract Number: 1285

Major Determinants of Prolonged Remission in Systemic Lupus Erythematosus: Retrospective Study over a 41-Year Period

8:30AM-10:30AM: Abstract Number: 1258

Measurement of Specific Organ Domains in Lupus Randomised Controlled Trials

8:30AM-10:30AM: Abstract Number: 1296

Mortality and Survival in Argentinian Lupus Patients: A Multicenter Study

8:30AM-10:30AM: Abstract Number: 1284

One Third of Lupus Nephritis Patients Classified as Complete Responders Continue to Accrue Progressive Renal Damage Despite Resolution of Proteinuria

8:30AM-10:30AM: Abstract Number: 1265

Paradoxical Effect of Vitamin D on Bone Mineral Density in SLE

8:30AM-10:30AM: Abstract Number: 1277

Patient Perspectives on Two Distinct Patterns of Type 2 SLE Symptoms

8:30AM-10:30AM: Abstract Number: 1289

Patients Enrolled in the Accelerating Medicines Partnership (AMP) RA/SLE Network with Isolated Renal Disease Report Minimal Quality of Life Impairment on PROMIS-29 Compared to Patients with Extrarenal Symptoms

8:30AM-10:30AM: Abstract Number: 1268

Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Comparison of Machine Learning Methods

8:30AM-10:30AM: Abstract Number: 1294

Predictors of BILAG-based Outcomes in Patients with SLE: Analysis from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort and MASTERPLANS Consortium

8:30AM-10:30AM: Abstract Number: 1276

Predictors of Remission (on and off Treatment) and Lupus Low Disease Activity State (LLDAS) in Systemic Lupus Erythematosus (SLE): Data from a Multinational, Multicenter SLICC (Systemic Lupus International Collaborating Clinics) Cohort

8:30AM-10:30AM: Abstract Number: 1266

Quality of Life Measures and Physical Activity in Childhood Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 1264

Racial Differences in Chronic Glucocorticoid Use in Patients with SLE: A Cross Sectional Study

8:30AM-10:30AM: Abstract Number: 1283

Reduction in Glucocorticoid Use in Patients with Systemic Lupus Erythematosus Treated with Belimumab: A Large Pooled Analysis of 5 Placebo-Controlled Studies

8:30AM-10:30AM: Abstract Number: 1291

Risk of Bleeding-related Complications After Kidney Biopsy in Patients with Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 1274

Severe Flares Are Associated with a Poorer Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients

8:30AM-10:30AM: Abstract Number: 1293

Studying Clusters of Patients with SLE According to Cognitive Function, Self-reported Outcomes, Disease Activity, and Clusters Dynamic over 1 Year

8:30AM-10:30AM: Abstract Number: 1292

Systemic Lupus Erythematous Readmissions Has Reduced in the Last Decade in the United States: A 9- year Longitudinal Study of the Nationwide Readmission Database

8:30AM-10:30AM: Abstract Number: 1269

The Burden of Systemic Lupus Erythematosus Patients in the United States – Evidence from the Medical Expenditure Panel Survey (2016-2018)

8:30AM-10:30AM: Abstract Number: 1261

The Impact of Remission and Low Disease Activity Attainment on Health-related Quality of Life in Two Phase III Clinical Trials of Belimumab in Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 1263

Treatment of Pediatric Lupus Is Associated with Significant Re-Organization of B Cell Chromatin

8:30AM-10:30AM: Abstract Number: 1286

Twenty-Year Trends in Systemic Lupus Erythematosus All–Cause Mortality in Mexico: A Nationwide Health Registry

8:30AM-10:30AM: Abstract Number: 1290

Validation of a Novel Lupus Multivariable Outcome Score as an Outcome Measure for Systemtic Lupus Erythematosus Trials

8:30AM-10:30AM: Abstract Number: 1302

Year-3 Observational Follow-up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE Who Completed a Phase 4, 52-Week, Randomized, Double-Blind Placebo-Controlled Safety Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].